Caribou Biosciences Inc (CRBU)
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
$0.41-7.22%
Close 2026-11-05 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-11-05
QuarterlyIQ Insights · CRBU
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -69.1% |
| Our one-year growth estimate | diamond | -17.9% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 51.2 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 117 industry peers
CRBU — CFO transition
Dated 2026-10-06
CFO — Sriram Ryali: The CFO's employment is set to terminate upon the execution of a strategic alternative, constituting a loss of a senior executive.
Why it matters: Caribou plans to stop both drug programs. Its cash plan and future spending may change.
Watch forA company filing states how much cash remains and names a funded plan beyond the current drug programs.
Also watch forA filing shows cash below $113.8 million with no new funding plan or clear limit on future spending.
Why it matters: Caribou plans major job and cost cuts as it stops two clinical programs. Their completion may show how fast costs are reset.
Watch forA filing or company update says the workforce cuts are mostly complete by December 31, 2026.
Also watch forA company update says the cuts are not mostly done by December 31, 2026. It may also report more steps to restructure.
Why it matters: A merger, sale, or asset deal could set the company's next path. The board has not set a review deadline.
Watch forThe board announces an approved merger, sale, or other deal with named terms.
Also watch forThe board ends the review without a deal, or reports that no acceptable deal was reached.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$269 on $10,000 · ±2.7% | How much price usually moves either way. |
| Bad day | $739 loss on $10,000 · 7.4% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $8,303 loss on $10,000 · 83.0% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.